Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: Reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Heal
Despite substantial risk reductions targeting low-density lipoprotein cholesterol with statins, there remains significant residual risk as evidenced by incident and recurrent CVD events among statin-treated patients. Observational studies have shown that low levels of high-density lipoprotein cholesterol (HDL-C) are associated with increased CVD risk. It remains unclear whether strategies aimed at increasing HDL-C in addition to background statin therapy will further reduce risk.
- Journal: Journal of the American College of Cardiology
- Year: 2012
- Topic: ASCVD (Atherosclerotic Cardiovascular Disease), Cholesterol / Lipids / Statins
- Read more articles by: Roger S. Blumenthal, MD, Michael Blaha, MD, MPH, Erin Michos, MD, MHS
